Archive: Company News

AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study

— Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical study

— AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical enzymes on the lining of the intestinal brush border

AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal diseases announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP in Frontiers in Immunology – Nutritional Immunology(https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1425982/full). AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine. AMYNOPEP is designed to break down hard-to-digest gluten peptides into harmless and absorbable single amino acids and dipeptides, thereby supporting individuals with gluten-related health disorders in avoiding exposure to inflammatory peptides. Read more…

Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA

— Performance: Statistically significant superiority over fat grafting, with breast volume retention twice as high

— Safety: BellaSeno’s scaffolds are safe and improve patient satisfaction and well-being

BellaSeno GmbH, an ISO 13485 certified tissue regeneration company developing resorbable scaffolds using additive manufacturing technologies, today announced that new clinical data from the first interim report of its ongoing study evaluating the use of BellaSeno’s 3D-printed resorbable breast scaffolds (ClinicalTrials.gov ID NCT05437757) were presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA, USA (Sept. 26 – 29, 2024).

Read more…

Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs

Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.

Read more…

ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base

— Existing investors and new investor Double Point Ventures join forces to support ImmunOs Therapeutics

— Investment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers

ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures as well as other existing investors. In conjunction with the round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.

Read more…

1 2 164